Leishmania donovani-derived lipophosphoglycan plus BCG induces a Th1 type immune response but does not protect Syrian golden hamsters (Mesocricetus auratus) and BALB/c mice against Leishmania donovani.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis; D001500:BCG Vaccine / Q000008:administration & dosage / Q000276:immunology*; D006224:Cricetinae; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D005434:Flow Cytometry; D006028:Glycosphingolipids / Q000008:administration & dosage / Q000276:immunology*; D006968:Hypersensitivity, Delayed; D007893:Leishmania donovani / Q000276:immunology*; D007898:Leishmaniasis, Visceral / Q000276:immunology* / Q000469:parasitology / Q000517:prevention & control; D008213:Lymphocyte Activation; D008297:Male; D008647:Mesocricetus; D051379:Mice; D008807:Mice, Inbred BALB C; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000276:immunology*; D013154:Spleen / Q000469:parasitology; D013601:T-Lymphocytes / Q000276:immunology
D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D001500:BCG Vaccine; D016207:Cytokines; D006028:Glycosphingolipids; D016052:Protozoan Vaccines; C008290:lipophosphonoglycan